JP2010510237A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510237A5 JP2010510237A5 JP2009537374A JP2009537374A JP2010510237A5 JP 2010510237 A5 JP2010510237 A5 JP 2010510237A5 JP 2009537374 A JP2009537374 A JP 2009537374A JP 2009537374 A JP2009537374 A JP 2009537374A JP 2010510237 A5 JP2010510237 A5 JP 2010510237A5
- Authority
- JP
- Japan
- Prior art keywords
- heteroaryl
- aryl
- compound according
- alkyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- -1 N- pyrrolidinyl Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000001686 pro-survival effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 0 CC(CC=C1)C(CN(CC2)CCN2c2cc3ncnc(NS(c(cc4)cc(*C(F)(F)F)c4N[C@](CCN4CCOCC4)CSc4ccccc4)(=C)=O)c3cc2)=C1c(cc1)ccc1Cl Chemical compound CC(CC=C1)C(CN(CC2)CCN2c2cc3ncnc(NS(c(cc4)cc(*C(F)(F)F)c4N[C@](CCN4CCOCC4)CSc4ccccc4)(=C)=O)c3cc2)=C1c(cc1)ccc1Cl 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85931506P | 2006-11-15 | 2006-11-15 | |
| US60/859,315 | 2006-11-15 | ||
| PCT/US2007/084873 WO2008061208A2 (en) | 2006-11-15 | 2007-11-15 | Arylsulfonamide compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010510237A JP2010510237A (ja) | 2010-04-02 |
| JP2010510237A5 true JP2010510237A5 (Direct) | 2011-01-27 |
| JP5366817B2 JP5366817B2 (ja) | 2013-12-11 |
Family
ID=39276199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537374A Active JP5366817B2 (ja) | 2006-11-15 | 2007-11-15 | アリールスルホンアミド化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8168645B2 (Direct) |
| EP (1) | EP2094672B1 (Direct) |
| JP (1) | JP5366817B2 (Direct) |
| CN (1) | CN101535280B (Direct) |
| AU (1) | AU2007319209B2 (Direct) |
| CA (1) | CA2666837C (Direct) |
| ES (1) | ES2423029T3 (Direct) |
| NZ (1) | NZ577442A (Direct) |
| WO (1) | WO2008061208A2 (Direct) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
| EP2252595B1 (en) | 2008-02-01 | 2014-03-26 | Takeda Pharmaceutical Company Limited | Oxim derivatives as hsp90 inhibitors |
| US20110098305A1 (en) * | 2008-05-21 | 2011-04-28 | Jonathan Bayldon Baell | Arylsulfonamide compounds, compositions and methods of use |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| EA020586B1 (ru) | 2009-09-10 | 2014-12-30 | Новартис Аг | СУЛЬФОНАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ СЕМЕЙСТВА Bcl-2, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ РАКА |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| EP2790725A4 (en) | 2011-12-13 | 2015-11-04 | Buck Inst For Res On Aging | METHODS FOR IMPROVING MEDICAL THERAPIES |
| EP2794591A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| CN104125955A (zh) | 2011-12-23 | 2014-10-29 | 诺华股份有限公司 | 用于抑制bcl2与结合配偶体相互作用的化合物 |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| CN110623956A (zh) | 2014-01-28 | 2019-12-31 | 巴克老龄化研究所 | 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物 |
| WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| JOP20190191A1 (ar) | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
| ES3013457T3 (en) | 2018-01-10 | 2025-04-14 | Recurium Ip Holdings Llc | Benzamide compounds as bci inhibitors for the treatment of hiv |
| CN108276395B (zh) * | 2018-02-09 | 2021-02-26 | 合肥华方医药科技有限公司 | 一种多沙唑嗪杂质的制备方法 |
| CN108570039B (zh) * | 2018-04-25 | 2022-09-23 | 上海美迪西生物医药股份有限公司 | 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用 |
| CN109851535A (zh) * | 2019-01-30 | 2019-06-07 | 天津现代职业技术学院 | 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法 |
| CN113248415B (zh) * | 2021-05-26 | 2022-08-09 | 苏州正永生物医药有限公司 | 一种abt-737关键中间体的制备方法以及abt-737的制备方法 |
| FI4426434T3 (fi) | 2021-11-02 | 2025-11-24 | Flare Therapeutics Inc | Pparg:n käänteisagonisteja ja niiden käyttöjä |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6720338B2 (en) * | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| EP1487811B1 (en) | 2002-03-21 | 2007-09-05 | Abbott Laboratories | N-sulfonylurea apoptosis promoters |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7642260B2 (en) * | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| US8614318B2 (en) * | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| TWI337180B (en) | 2003-11-20 | 2011-02-11 | Mitsubishi Gas Chemical Co | Liquid cyclohexanetricarboxylic acid anhydride |
| ATE542796T1 (de) * | 2004-05-26 | 2012-02-15 | Abbott Lab | N-sulfonylcarboximidamidverbindungen als apoptosepromotoren |
| US8557812B2 (en) * | 2004-08-20 | 2013-10-15 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof |
| US8101619B2 (en) * | 2004-12-08 | 2012-01-24 | Solvay Pharmaceuticals B.V. | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition |
| TWI337182B (en) * | 2005-05-12 | 2011-02-11 | Abbott Lab | Apoptosis promoters |
-
2007
- 2007-11-15 EP EP07864478.8A patent/EP2094672B1/en active Active
- 2007-11-15 CA CA2666837A patent/CA2666837C/en active Active
- 2007-11-15 CN CN2007800426055A patent/CN101535280B/zh active Active
- 2007-11-15 AU AU2007319209A patent/AU2007319209B2/en active Active
- 2007-11-15 NZ NZ577442A patent/NZ577442A/en unknown
- 2007-11-15 WO PCT/US2007/084873 patent/WO2008061208A2/en not_active Ceased
- 2007-11-15 US US12/513,835 patent/US8168645B2/en active Active
- 2007-11-15 JP JP2009537374A patent/JP5366817B2/ja active Active
- 2007-11-15 ES ES07864478T patent/ES2423029T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510237A5 (Direct) | ||
| JP2010501584A5 (Direct) | ||
| JP2013500314A5 (Direct) | ||
| JP2017537940A5 (Direct) | ||
| JP2012524055A5 (Direct) | ||
| RU2009126745A (ru) | Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств | |
| JP2012519691A5 (Direct) | ||
| JP2013508279A5 (Direct) | ||
| JP2018507890A5 (Direct) | ||
| JP2007519649A5 (Direct) | ||
| JP2013056886A5 (Direct) | ||
| JP2011057693A5 (Direct) | ||
| JP2018526399A5 (Direct) | ||
| JP2020532547A5 (Direct) | ||
| JP2010524947A5 (Direct) | ||
| JP2009535307A5 (Direct) | ||
| JP2010524932A5 (Direct) | ||
| JP2014524472A5 (Direct) | ||
| JP2011526924A5 (Direct) | ||
| JP2012522847A5 (Direct) | ||
| JP2009513703A5 (Direct) | ||
| JP2011521911A5 (Direct) | ||
| JP2019500387A5 (Direct) | ||
| RU2007124329A (ru) | ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ | |
| JP2013529210A5 (Direct) |